Agree wolfi, and as AMS started amiss even on the 1b AML results ( the original cohort of 15), yet reported on the 1b and 2a breastcancer, and the 1b Ovarian cancer readouts. Agree, If reporting practices improve then shareholders could get a more comprehensive understanding of results.
Quarter out soon, maybe someone on the team is taking note.., maybe not.
Ann: PTX-200 AML Trial Progresses to Higher Dose, page-36
Add PTX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.0¢ |
Change
-0.004(9.09%) |
Mkt cap ! $33.01M | |||
| Open | High | Low | Value | Volume |
| 4.2¢ | 4.3¢ | 4.0¢ | $11.08K | 263.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 219550 | 4.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.3¢ | 172342 | 1 |
View Market Depth
| Last trade - 16.10pm 10/07/2024 (20 minute delay) ? |
| PTX (ASX) Chart |